KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $136.7 million.

  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) rose 12.33% to $136.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $525.1 million, marking a year-over-year increase of 11.84%. This contributed to the annual value of $482.9 million for FY2024, which is 14.70% up from last year.
  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) amounted to $136.7 million in Q3 2025, which was up 1.18% from $135.1 million recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $136.7 million in Q3 2025 and a low of $67.4 million during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $120.7 million (2024), whereas its average is $118.4 million.
  • Data for Regeneron Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY soared of 38.58% (in 2023) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $74.5 million in 2021, then soared by 34.36% to $100.1 million in 2022, then rose by 12.89% to $113.0 million in 2023, then rose by 11.86% to $126.4 million in 2024, then rose by 12.33% to $136.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $136.7 million for Q3 2025, versus $135.1 million for Q2 2025 and $126.9 million for Q1 2025.